Mgi Tech Co Ltd.

SHENZHEN, China, Oct. 28, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced entering into an exclusive licensing agreement through its US subsidiaries – MGI US LLC and Complete Genomics Inc. – with Swiss Rockets AG, a Switzerland-based biotech firm, for the research, development, manufacture, and commercialization of exclusive sequencing products based on MGI's CoolMPS™ technology and non-exclusive accessory products outside the Asia-Pacific and Greater China regions (i.e., Chinese Mainland, Hong Kong, Macau, and Taiwan). The strategic partnership is set to fully unlock the patent value and productization capabilities of CoolMPS, complementing MGI's tried-and-true StandardMPS™ technology and cementing the company's leadership in the field of genomic sequencing.

CoolMPS technology, distinguished by its innovative antibody-based recognition chemistry, represents a breakthrough in sequencing by eliminating DNA "scarring", a common issue found in conventional long-read methods. It employs nucleotides with natural bases and extension blocks, combined with labeled antibodies that are both base-specific and block-dependent. The CoolMPS method links each nucleotide with labeled multiple fluorescent dye antibodies.

Deployed on MGI's DNBSEQ™ platforms, CoolMPS delivers sequencing reads reaching up to 600 to 700 bases, covering comprehensive genome, transcriptome, and microbiome analyses. Its high fidelity enables crucial applications including early cancer detection and monitoring through whole genome sequencing-based assays, providing scientists, researchers and the wider life science sector with longer and more accurate reads at reduced costs.

Under the licensing agreement, Swiss Rockets is granted exclusive rights to MGI's CoolMPS-related intellectual property, including patents, know-how, and software, to research, develop, manufacture, and commercialize relevant products for global markets excluding Asia-Pacific and Greater China.

Swiss Rockets, reinforced by an investment agreement with leading US public health company Emergent BioSolutions, will leverage the license to further expand CoolMPS's global reach and applications by manufacturing CoolMPS sequencers and consumables for markets including US and Europe. The technology and its products will also be used to augment the company's personalized disease and aging prevention and optimal disease treatments aimed at precision longevity and medicine.

"This partnership marks a pivotal step for MGI to maximize the impact of CoolMPS worldwide by joining forces with a like-minded innovator to commercialize and scale this groundbreaking sequencing technology for improving global health," said Dr Rade Drmanac, Chief Scientific Officer of MGI. "For our customers, partners, and investors, this also injects renewed confidence in MGI's financial strength, business focus and technological leadership, providing the global life science community once again with the right to another choice."

"We are excited to license CoolMPS from MGI, enabling Swiss Rockets to advance our mission in oncology and viral disease innovation through world-class technology," added Dr. Vladimir Cmiljanovic, CEO of Swiss Rockets. "CoolMPS complements our drug development pipelines and diagnostic platforms, reinforcing our capabilities to deliver precise, personalized solutions for patients and communities in need."

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.

About Swiss Rockets AG

Swiss Rockets AG, as both an incubator and accelerator, supports growth of biotech and precision healthcare start-ups, particularly in the field of oncology. It's portfolio of radioligand therapies, small moleculs and vaccines in pre-clinical and clinical stage, already drew attention of the best global pharmaceutical companies for future partnerships. Swiss Rockets AG was founded by a team consisting of Dr. Vladimir Cmiljanovic, Chief Executive Officer; Dr. Natasa Cmiljanovic, Chief Operating Officer; Manuel Ebner, Dr. Thomas Sander, and Dr. Thomas Staehelin.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mgi-tech-announces-exclusive-licensing-agreement-with-swiss-rockets-ag-to-globalize-proprietary-coolmpsa-sequencing-technology-302597806.html

SOURCE MGI TECH

SHENZHEN, China, April 13, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, proudly marks a decade since the commercialization of its proprietary DNBSEQ™ sequencing technology. Over the past ten years, DNBSEQ™ has transformed the landscape of genomics by delivering high-performance, cost-effective sequencing solutions that empower scientists, clinicians, and innovators across the globe.

First commercial launched in 2015, DNBSEQ™ has become a trusted platform for cutting-edge research and diagnostics—spanning over 3,900 installations worldwide and contributing to more than 10,900 peer-reviewed publications*. Today, DNBSEQ™ continues to stand at the forefront of sequencing innovation, driving progress in precision medicine, public health, agriculture, biodiversity, and more.

A Decade of Speed and Scale in Innovation

Powered by proprietary DNA nanoball (DNB) technology and patterned arrays, DNBSEQ™ delivers exceptional accuracy, lower duplication rates, and minimal index hopping—resulting in high-quality data at significantly lower cost. These advantages make it an ideal choice for both large-scale studies and sensitive clinical applications.DNBSEQä technology has been widely praised by users for its outstanding data quality and cost-effectiveness in different applications, including whole-genome sequencing (WGS) and whole-exome sequencing (WES). Research has also identified the platform as an excellent candidate for eukaryotic genome sequencing, metagenomic sequencing, bacterial genome research, and more, demonstrating its versatility and reliability across scenarios.

DNBSEQ™ has redefined the speed of innovation in genomic technology, offering the widest range of sequencing throughput and application coverage in the industry. Today, MGI offers a comprehensive portfolio of genetic sequencers based on DNBSEQä under T, G, and E series, including the ultra-high-throughput DNBSEQ-T20×2 which delivered the world's first sub-$100 human genome; the widely adopted DNBSEQ-T7 for high-throughput versatility; the ultra-compact DNBSEQ-E25 designed for fieldwork and decentralized testing; the benchtop DNBSEQ-G400;and the fastest in its class for mid-to-low throughput sequencing DNBSEQ-G99; MGI's newest flagship, the DNBSEQ-T1+, represents the latest evolution of this journey—an ultra-fast benchtop sequencer that balances power, speed, and flexibility. It reflects MGI's ongoing commitment to continuous innovation, empowering researchers to accelerate discovery without compromise.

Enabling Multi-Omics and Real-World Impact

More than a sequencing platform, DNBSEQ™ enables a wide range of multi-omics applications—including genomics, transcriptomics, epigenomics, single-cell, and spatial omics. These capabilities make it a powerful tool across diverse scientific fields, enabling deeper insights into disease mechanisms, environmental interactions, and biological systems.

Proven in extreme environments—from the depths of the Mariana Trench to the peak of Mount Everest—DNBSEQ™ continues to deliver high-quality, reliable results wherever science needs to go.

End-to-End Solutions: Making Science Simpler

MGI complements its sequencing platforms with a suite of automation and BIT tools that deliver a seamless end-to-end workflow—from sample preparation to data analysis. These integrated solutions improve efficiency, reduce manual effort, and bring advanced genomic tools within reach for more users, regardless of lab size or location.

Inspired by the question "What if science had no barriers?", MGI's technology ecosystem is designed to remove bottlenecks and lower costs, enabling researchers to focus on discovery—not complexity.

Toward the $10 Genome and a More Equitable Future

As MGI looks to the future, the company is focused on achieving its most ambitious goal yet: the $10 genome. Building on the foundation of DNBSEQ™, MGI is developing next-generation sequencing technologies to further reduce costs, increase accessibility, and accelerate time to insight.

"Over the past decade, DNBSEQ™ has grown from an innovation into a global standard for high-quality, affordable sequencing," said Dr. Rade Drmanac, Chief Scientific Officer at MGI. "We've opened doors for researchers everywhere—and now, we're building the next chapter in accessible genomics."

Genomics for All: The Mission Continues

Celebrating 10 years of DNBSEQ™ is more than a technological milestone—it is a reaffirmation of MGI's mission: to make genomics accessible, affordable, and impactful for all. By delivering the tools that drive discovery, MGI is helping to build a healthier, more informed, and more connected world—one genome at a time.

For more information on DNBSEQ™ technology and MGI's full product portfolio, visit: https://en.mgi-tech.com

* statistics as of 30 Jun 2024

About MGI 

MGI Tech Co., Ltd.  (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/ , Linkedin, X, and Youtube.  

View original content to download multimedia:https://www.prnewswire.com/news-releases/mgi-tech-celebrates-10-years-of-dnbseq-technology-driving-genomics-forward-with-speed-scale-and-accessibility-302427245.html

SOURCE MGI TECH